After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo …
Amid Novartis’ strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were considering …
Amid the industrywide push by Big Pharmas to spin off their generics and consumer businesses, Novartis may be on the verge of separating itself from …
When Amgen bought marketing rights to psoriasis pill Otezla for $13.4 billion two years ago, the company was likely counting on not having to compete …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
